News for Intellia Therapeutics, Inc. (NTLA)

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage gene editing company focused on revolutioniz

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. ( NTLA). Sharehold

PR NewswireNEW YORK, March 3, 2025 NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intel

PR NewswireNEW YORK, March 3, 2025 NEW YORK, March 3, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder

PR NewswireNEW YORK, March 3, 2025 NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Thera

Cash Equivalents and Marketable Securities: Approximately $861.7 million as of December 31, 2024, compared to $1 billion as of December 31, 2023.Collaboration

Feb 27, 2025 / 01:00PM GMTOperator Good morning and welcome to Intellia Therapeutics' fourth quarter and full year 2024 financial results conference call. My na

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ETCompany ParticipantsBrittany Chaves - Senior Manager...

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 6.06% and 45.95%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics Inc (NTLA), a leader in clinical-stage gene editing, announced significant advancements in its CRISPR-based therapies, including the dosin

PR NewswireNEW YORK, Feb. 25, 2025 NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intel

On February 25, 2025, Bernstein Liebhard LLP, a prominent investor rights law firm, announced a securities fraud class action lawsuit against Intellia Therapeut

Intellia Therapeutics Inc (NTLA) is currently facing a class action securities lawsuit, as announced by Levi & Korsinsky, LLP on February 25, 2025. The lawsuit

PR NewswireLOS ANGELES, Feb. 25, 2025 LOS ANGELES, Feb. 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, remind

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Intellia Therapeutics, Inc. ( NTLA)?Did you purchase yo

PR NewswireNEW YORK, Feb. 24, 2025 NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeut

PR NewswireNEW YORK, Feb. 24, 2025 NEW YORK, Feb. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Thera

Intellia Therapeutics Inc (NTLA), a clinical-stage gene editing company, is under scrutiny as Robbins LLP announces a class action lawsuit filed on behalf of in